Form 4 for CRL Charles River Laboratories
Accepted 2022-03-02 00:00:00 ET · period of report 2022-02-28 · accession 0001127602-22-007805 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-02 | 2022-02-28 | CRL | Smith David Ross | CFO, Corp. Executive VP | A - Grant | $0.00 | +5,152 | 25.8K | +25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-28 | A | A | 5,152 | $0.00 | 25,819 | D | — | — | (F1) Unvested restricted stock units vest as follows: 5,152 on February 28, 2023. |